Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Arata Azuma(Nippon Medical School Hospital), Yoshio Taguchi(Sapporo Medical University), Shoji Kudoh(Japan Anti Tuberculosis Association), Koichiro Nakata(Sapporo Medical University), Atsuhiko Sato(Sapporo Medical University), Shosaku Abe(Sapporo Medical University), Moritaka Suga(Saiseikai Kumamoto Hospital), Eiyasu Tsuboi(Sapporo Medical University), Sonoko Nagai(Sapporo Medical University), Toshihiro Nukiwa(Tohoku University), Harumi Itoh(Sapporo Medical University), Motoharu Ohi(Sapporo Medical University)
American Journal of Respiratory and Critical Care Medicine
January 21, 2005
10.1164/rccm.200404-571oc
Cited by 953

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
|Journal of Clinical Oncology|2009|516